| Product NDC: | 50268-061 |
| Proprietary Name: | Acyclovir |
| Non Proprietary Name: | Acyclovir |
| Active Ingredient(s): | 400 mg/1 & nbsp; Acyclovir |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 50268-061 |
| Labeler Name: | AvPAK |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA075382 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19990305 |
| Package NDC: | 50268-061-15 |
| Package Description: | 50 TABLET in 1 BOX, UNIT-DOSE (50268-061-15) |
| NDC Code | 50268-061-15 |
| Proprietary Name | Acyclovir |
| Package Description | 50 TABLET in 1 BOX, UNIT-DOSE (50268-061-15) |
| Product NDC | 50268-061 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Acyclovir |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 19990305 |
| Marketing Category Name | ANDA |
| Labeler Name | AvPAK |
| Substance Name | ACYCLOVIR |
| Strength Number | 400 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |